Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Compared with low-dose aspirin, high-dose aspirin was associated with a trend to a higher hazard of bleeding (adjusted HR for GUSTO severe bleeding: 1.88 [high dose] versus 1.63 [low dose]; P -interaction=0.954) and less efficacy (adjusted HR for primary efficacy end-point event: 1.05 [high dose] versus 0.90 [low dose]; P -interaction=0.140) with vorapaxar compared with placebo, although this did not reach statistical significance. 53 Pharmacodynamic substudy A pharmacodynamic substudy enrolling a total of 249 patients in TRACER was conducted. 54 Pharmacodynamic assessments were conducted at baseline and 1 month after study enrollment in patients on aspirin and clopidogrel, and included light-transmission aggregometry follow

also in 111,027 other papers